All In Biotech

Drug Trial Radar · NCT01986088

Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study

A Multicentre, Double Blind, Double Dummy, Parallel Group, Placebo Controlled, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels Oral Sumatriptan Given for the Acute Treatment of Migraine(With and Without Aura).

Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,008 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,008

Actual

Start

Nov 1996

Primary completion

Jan 1998

Study completion Jan 1998

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 76 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A previously published, placebo-controlled, head-to-head comparator study found eletriptan to have superior efficacy to oral sumatriptan 100 mg in treating a single acute migraine attack. The goal of the current study was to extend the findings of that study by examining the efficacy of eletriptan compared with both 50- and 100-mg doses of sumatriptan; and to evaluate the comparative efficacy of eletriptan and sumatriptan across additional important clinical outcomes. In particular, early response (at 1 hour), sustained response (without need for additional treatment) at 24 hours, and consistency of response across multiple attacks were examined.

Conditions

  • Migraine With or Without Aura

Interventions

  • PlaceboDrug

    matching placebo

  • Eletriptan 40 mgDrug

    40mg oral

  • Eletriptan 80 mgDrug

    80mg oral

  • Sumatriptan 50 mgDrug

    50mg oral

  • Sumatriptan 100 mgDrug

    100mg oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Headache response at 1 hour after treatment of the first attack.Time frame: 1 hour

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.